Tg Therapeutics Inc Financials
Tg Therapeutics Inc (TGTX) reported $799.5M in revenue over the twelve months to Jun 30, 2026, up 76.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Commercial growth is expanding margins, but cash conversion lags badly because reported profit is outrunning collections.
In FY2025, net income of$447.2M sat far above operating income of$123.3M , helped by a large tax benefit rather than only by core operations. That combination is an earnings-quality signal: operating cash flow remained negative while receivables and inventory kept building, so reported profit improved faster than the business converted sales into cash.
From FY2023 to FY2025, operating margin widened from
The balance sheet looks less levered on paper as debt-to-equity fell from 1.1x to 0.4x, but that mostly reflects a bigger equity base, not a major paydown of debt. Meanwhile cash liquidity fell to
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Tg Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Tg Therapeutics Inc has an operating margin of 20.0%, meaning the company retains $20 of operating profit per $100 of revenue. This strong profitability earns a score of 66/100, reflecting efficient cost management and pricing power. This is up from 12.7% the prior year.
Tg Therapeutics Inc's revenue surged 87.3% year-over-year to $616.3M, reflecting rapid business expansion. This strong growth earns a score of 96/100.
Tg Therapeutics Inc has a moderate D/E ratio of 0.38. This balance of debt and equity financing earns a leverage score of 39/100.
With a current ratio of 4.10, Tg Therapeutics Inc holds $4.10 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 86/100.
Tg Therapeutics Inc's operations used $24.8M of cash, and capex of $214K added to the outflow, for a free cash flow shortfall of $25.0M. This results in a cash flow score of 17/100.
Tg Therapeutics Inc's ROE of 69.0% shows moderate profitability relative to equity, earning a score of 57/100. This is up from 10.5% the prior year.
Tg Therapeutics Inc scores 12.25, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($8.4B) relative to total liabilities ($415.2M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Tg Therapeutics Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Tg Therapeutics Inc used $0.06 of operating cash (-$24.8M OCF vs $447.2M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Tg Therapeutics Inc earns $4.61 in operating income for every $1 of interest expense ($123.3M vs $26.7M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Earnings & Revenue
Tg Therapeutics Inc generated $616.3M in revenue in fiscal year 2025. This represents an increase of 87.3% from the prior year.
Tg Therapeutics Inc's EBITDA was $123.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 193.8% from the prior year.
Tg Therapeutics Inc reported $447.2M in net income in fiscal year 2025. This represents an increase of 1811.1% from the prior year.
Tg Therapeutics Inc earned $2.77 per diluted share (EPS) in fiscal year 2025. This represents an increase of 1746.7% from the prior year.
Cash & Balance Sheet
Tg Therapeutics Inc recorded an outflow of $25.0M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 38.4% from the prior year.
Tg Therapeutics Inc held $79.1M in cash against $245.6M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Tg Therapeutics Inc's gross margin was 83.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 4.6 percentage points from the prior year.
Tg Therapeutics Inc's operating margin was 20.0% in fiscal year 2025, reflecting core business profitability. This is up 7.3 percentage points from the prior year.
Tg Therapeutics Inc's net profit margin was 72.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 65.5 percentage points from the prior year.
Tg Therapeutics Inc's ROE was 69.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 58.5 percentage points from the prior year.
Capital Allocation
Tg Therapeutics Inc invested $160.2M in research and development in fiscal year 2025. This represents an increase of 69.9% from the prior year.
Tg Therapeutics Inc spent $91.2M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 941.6% from the prior year.
Tg Therapeutics Inc invested $214K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 375.6% from the prior year.
TGTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $240.3M+17.3% | $204.9M+6.4% | $192.6M+19.1% | $161.7M+14.6% | $141.1M+16.8% | $120.9M+11.7% | $108.2M+29.0% | $83.9M |
| Cost of Revenue | $41.2M+22.9% | $33.5M-12.1% | $38.1M+35.8% | $28.1M+48.3% | $18.9M+21.9% | $15.5M+0.9% | $15.4M+64.9% | $9.3M |
| Gross Profit | $199.1M+16.2% | $171.4M+11.0% | $154.4M+15.6% | $133.6M+9.3% | $122.2M+16.0% | $105.3M+13.5% | $92.8M+24.5% | $74.5M |
| R&D Expenses | $95.3M+97.0% | $48.4M+17.5% | $41.2M+0.8% | $40.9M+28.6% | $31.8M-31.4% | $46.4M+94.2% | $23.9M+18.6% | $20.1M |
| SG&A Expenses | $82.1M-6.9% | $88.2M+40.6% | $62.7M-1.0% | $63.4M+14.0% | $55.6M+10.4% | $50.3M+29.2% | $39.0M-7.2% | $42.0M |
| Operating Income | $21.7M-37.7% | $34.8M-31.1% | $50.5M+72.0% | $29.4M-15.7% | $34.8M+304.1% | $8.6M-71.2% | $29.9M+140.9% | $12.4M |
| Interest Expense | $16.6M+116.2% | $7.7M+17.3% | $6.5M-2.8% | $6.7M+0.1% | $6.7M-0.6% | $6.8M-2.5% | $6.9M-36.0% | $10.8M |
| Income Tax | $2.5M+318.6% | $586K-97.3% | $22.1M+106.0% | -$365.0M-13454.8% | $2.7M+569.9% | $408K-80.8% | $2.1M+446.9% | $388K |
| Net Income | $7.8M-60.7% | $19.8M-14.2% | $23.1M-94.1% | $390.9M+1286.8% | $28.2M+457.1% | $5.1M-78.3% | $23.3M+501.8% | $3.9M |
| EPS (Diluted) | $0.05-58.3% | $0.12-20.0% | $0.15-93.8% | $2.43+1329.4% | $0.17+466.7% | $0.03-80.0% | $0.15+650.0% | $0.02 |
TGTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.6B+7.2% | $1.5B+43.8% | $1.1B+3.7% | $1.0B+45.9% | $702.6M+7.0% | $656.7M+13.7% | $577.7M-1.4% | $586.0M |
| Current Assets | $1.1B+5.4% | $1.1B+72.3% | $630.8M+5.2% | $599.8M-9.7% | $664.0M+3.0% | $644.5M+13.8% | $566.4M-1.3% | $574.1M |
| Cash & Equivalents | $482.6M+9.1% | $442.2M+458.7% | $79.1M+6.8% | $74.1M-42.6% | $129.1M-2.3% | $132.1M-26.5% | $179.9M-8.1% | $195.8M |
| Inventory | $148.0M+14.7% | $129.0M+2.7% | $125.6M-14.5% | $147.0M-5.3% | $155.2M-1.6% | $157.8M+42.8% | $110.5M+30.5% | $84.7M |
| Accounts Receivable | $401.6M+2.4% | $392.0M+28.3% | $305.6M+15.2% | $265.4M+14.6% | $231.5M+21.8% | $190.1M+47.2% | $129.2M+11.6% | $115.7M |
| Total Liabilities | $1.0B+9.5% | $945.7M+127.8% | $415.2M-0.6% | $417.8M-2.0% | $426.2M+1.6% | $419.4M+18.0% | $355.3M-9.8% | $393.9M |
| Current Liabilities | $268.5M+43.5% | $187.1M+21.7% | $153.8M-1.9% | $156.8M-8.8% | $171.9M+7.3% | $160.2M+76.7% | $90.7M-27.5% | $125.1M |
| Long-Term Debt | $745.4M0.0% | $745.1M+203.3% | $245.6M+0.1% | $245.3M+0.1% | $245.0M+0.1% | $244.7M+0.1% | $244.4M+0.1% | $244.2M |
| Total Equity | $604.1M+3.6% | $583.1M-10.0% | $648.0M+6.7% | $607.2M+119.7% | $276.4M+16.5% | $237.3M+6.7% | $222.4M+15.7% | $192.2M |
| Retained Earnings | -$1.1B+0.7% | -$1.1B+1.8% | -$1.1B+2.1% | -$1.1B+26.1% | -$1.5B+1.8% | -$1.5B+0.3% | -$1.5B+1.5% | -$1.6B |
Not reported in any period shown, so not listed: Goodwill.
TGTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $39.3M+319.4% | -$17.9M-191.0% | $19.7M+184.9% | -$23.2M-411.4% | $7.4M+125.9% | -$28.7M-12.0% | -$25.6M-110.1% | -$12.2M |
| Capital Expenditures | $293K+474.5% | $51K-23.9% | $67K-16.3% | $80K+90.5% | $42K+68.0% | $25K+19.0% | $21K-12.5% | $24K |
| Free Cash Flow | $39.0M+317.2% | -$17.9M-191.6% | $19.6M+184.3% | -$23.2M-414.2% | $7.4M+125.7% | -$28.7M-12.0% | -$25.7M-109.8% | -$12.2M |
| Investing Cash Flow | $1.0M+110.4% | -$9.9M+36.9% | -$15.6M-133.7% | $46.4M+1261.4% | -$4.0M+69.1% | -$12.9M-181.9% | $15.8M+269.1% | -$9.3M |
| Financing Cash Flow | $85K-100.0% | $390.8M+36840.4% | $1.1M+101.4% | -$78.2M-1114.4% | -$6.4M-5.6% | -$6.1M-0.5% | -$6.1M-104.5% | $134.5M |
| Share Buybacks | $0-100.0% | $100.0M | $0-100.0% | $78.2M+1038.1% | $6.9M+12.3% | $6.1M-7.4% | $6.6M+207.6% | $2.1M |
Not reported in any period shown, so not listed: Dividends Paid.
TGTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.9%-0.8pp | 83.7%+3.5pp | 80.2%-2.4pp | 82.6%-3.9pp | 86.6%-0.6pp | 87.1%+1.4pp | 85.8%-3.1pp | 88.9% |
| Operating Margin | 9.0%-8.0pp | 17.0%-9.2pp | 26.2%+8.1pp | 18.2%-6.5pp | 24.7%+17.6pp | 7.1%-20.5pp | 27.7%+12.9pp | 14.8% |
| Net Margin | 3.2%-6.4pp | 9.7%-2.3pp | 12.0% | 241.7% | 20.0%+15.8pp | 4.2%-17.4pp | 21.6%+16.9pp | 4.6% |
| Return on Equity | 1.3%-2.1pp | 3.4%-0.2pp | 3.6%-60.8pp | 64.4%+54.2pp | 10.2%+8.1pp | 2.1%-8.4pp | 10.5%+8.5pp | 2.0% |
| Return on Assets | 0.5%-0.8pp | 1.3%-0.9pp | 2.2%-36.0pp | 38.1%+34.1pp | 4.0%+3.2pp | 0.8%-3.3pp | 4.0%+3.4pp | 0.7% |
| Current Ratio | 4.27-1.5x | 5.81+1.7x | 4.10+0.3x | 3.820.0x | 3.86-0.2x | 4.02-2.2x | 6.25+1.7x | 4.59 |
| Debt-to-Equity | 1.230.0x | 1.28+0.9x | 0.380.0x | 0.40-0.5x | 0.89-0.1x | 1.03-0.1x | 1.10-0.2x | 1.27 |
| FCF Margin | 16.2%+25.0pp | -8.8%-18.9pp | 10.2%+24.5pp | -14.4%-19.6pp | 5.2%+29.0pp | -23.8%-0.1pp | -23.7%-9.1pp | -14.6% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Similar Companies
Where Tg Therapeutics Inc Ranks
Frequently Asked Questions
What is Tg Therapeutics Inc's annual revenue?
Tg Therapeutics Inc (TGTX) reported $616.3M in total revenue for fiscal year 2025. This represents a 87.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Tg Therapeutics Inc's revenue growing?
Tg Therapeutics Inc (TGTX) revenue grew by 87.3% year-over-year, from $329.0M to $616.3M in fiscal year 2025.
Is Tg Therapeutics Inc profitable?
Yes, Tg Therapeutics Inc (TGTX) reported a net income of $447.2M in fiscal year 2025, with a net profit margin of 72.6%.
What is Tg Therapeutics Inc's EBITDA?
Tg Therapeutics Inc (TGTX) had EBITDA of $123.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Tg Therapeutics Inc have?
As of fiscal year 2025, Tg Therapeutics Inc (TGTX) had $79.1M in cash and equivalents against $245.6M in long-term debt.
What is Tg Therapeutics Inc's gross margin?
Tg Therapeutics Inc (TGTX) had a gross margin of 83.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Tg Therapeutics Inc's operating margin?
Tg Therapeutics Inc (TGTX) had an operating margin of 20.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Tg Therapeutics Inc's net profit margin?
Tg Therapeutics Inc (TGTX) had a net profit margin of 72.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Tg Therapeutics Inc's return on equity (ROE)?
Tg Therapeutics Inc (TGTX) has a return on equity of 69.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Tg Therapeutics Inc's free cash flow?
Tg Therapeutics Inc (TGTX) recorded an outflow of $25.0M in free cash flow during fiscal year 2025. This represents a 38.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Tg Therapeutics Inc's operating cash flow?
Tg Therapeutics Inc (TGTX) recorded an outflow of $24.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Tg Therapeutics Inc's total assets?
Tg Therapeutics Inc (TGTX) had $1.1B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Tg Therapeutics Inc's capital expenditures?
Tg Therapeutics Inc (TGTX) invested $214K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Tg Therapeutics Inc spend on research and development?
Tg Therapeutics Inc (TGTX) invested $160.2M in research and development during fiscal year 2025.
What is Tg Therapeutics Inc's current ratio?
Tg Therapeutics Inc (TGTX) had a current ratio of 4.10 as of fiscal year 2025, which is generally considered healthy.
What is Tg Therapeutics Inc's debt-to-equity ratio?
Tg Therapeutics Inc (TGTX) had a debt-to-equity ratio of 0.38 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Tg Therapeutics Inc's return on assets (ROA)?
Tg Therapeutics Inc (TGTX) had a return on assets of 42.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Tg Therapeutics Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Tg Therapeutics Inc (TGTX) held $201.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $24.8M over that year. Dividing the one by the other, the reported balance equals about 97 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Tg Therapeutics Inc's Altman Z-Score?
Tg Therapeutics Inc (TGTX) has an Altman Z-Score of 12.25, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Tg Therapeutics Inc's Piotroski F-Score?
Tg Therapeutics Inc (TGTX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Tg Therapeutics Inc's earnings high quality?
For every $1 of reported earnings, Tg Therapeutics Inc (TGTX) used $0.06 of operating cash (-$24.8M OCF vs $447.2M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Tg Therapeutics Inc cover its interest payments?
Tg Therapeutics Inc (TGTX) has an interest coverage ratio of 4.61x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Tg Therapeutics Inc?
Tg Therapeutics Inc (TGTX) scores 60 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.